During the last decades, the prognosis of Hodgkin lymphoma (HL) has been improved
significantly with the introduction of effective chemotherapy and the implementation of risk …

Relapsed or refractory Hodgkin lymphoma is a challenging problem for clinicians who treat
hematologic malignancies. The standard management of these patients should include the …

The majority of patients with Hodgkin lymphoma (HL) can now expect to be cured with
conventional chemo‐and/or radio‐therapy. However, a subgroup still exists that have poor …

Hodgkin's lymphoma (HL) patients with positive 18 F-fluorodeoxyglucose positron emission
tomography (FDG-PET) post salvage chemotherapy or before high-dose chemotherapy and …

Patients with classical Hodgkin lymphoma (cHL) typically receive first-line chemotherapy or
chemoradiotherapy, and cure rates are high [1]. However, some patients may have primary …

The study was to determine clinical utility of serum soluble interleukin (IL)‐2 receptor (sIL‐
2Rα), β2‐microglobulin (β2‐M), lactate dehydrogenase (LDH) and erythrocyte …

Background The use of high-dose chemotherapy and autologous stem-cell transplantation
in patients with relapsed Hodgkin's lymphoma is supported by two randomized clinical trials …

Optimal conditioning remains a challenge in lymphomas. We designed a regimen consisting
of Busulfex, etoposide and melphalan (BuEM). We retrospectively analyzed the outcome of …

The purpose of this national retrospective study was to evaluate the outcome in children with
relapsed or primary refractory Hodgkin lymphoma [HL] after a primary chemotherapy alone …

Classical Hodgkin lymphoma (cHL) is a relatively rare disease, with approximately 9,200
estimated new cases and 1,200 estimated deaths per year in the United States. First-line …